Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVX-508
- Development stage
- Unknown
- Lead developer
- NuvOx Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
NVX-508 is an investigational oxygen-carrying perfluorocarbon emulsion developed by NuvOx Pharma specifically for the treatment of sickle cell disease (SCD). The formulation consists of dodecafluoropentane (DDFP) droplets that act as a highly efficient oxygen transport vehicle. Upon intravenous administration, these droplets facilitate the transfer of oxygen from the lungs to the blood and from red blood cells to hypoxic tissues. By enhancing oxygen delivery to diseased tissues, NVX-508 aims to prevent the polymerization of sickle hemoglobin, thereby reducing the sickling of red blood cells and mitigating clinical complications such as vaso-occlusive episodes (VOE) and acute chest syndrome (ACS). It is currently being evaluated in a Phase 1b dose-finding study led by investigators at the University of Pittsburgh to establish safety and the maximum tolerated dose in patients with steady-state sickle cell disease.
- Other names
- Dodecafluoropentane emulsionDDFPe
Beyond the preview
Go deeper on NVX-508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVX-508.